Intraperitoneal Infusion of ex Vivo-cultured Allogeneic NK Cells in Recurrent Ovarian Carcinoma Patients (a Phase I Study)
Phase of Trial: Phase I
Latest Information Update: 17 Jan 2020
Price : $35 *
At a glance
- Drugs GCT NK cell therapy (Primary) ; Cyclophosphamide; Fludarabine
- Indications Carcinoma; Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Adverse reactions
- Acronyms INTRO
- 17 Jan 2020 Last checked against ClinicalTrials.gov record.
- 12 Sep 2019 Status changed from not yet recruiting to recruiting.
- 29 Mar 2019 Planned initiation date changed from 1 Nov 2018 to 1 Apr 2019.